Loading
Latest filing published 04 Oct 2024 for Augmedix, Inc., €16k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Ian Shakil (senior executive) discloses dealings in Augmedix, Inc. to SEC (Form 4). The record holds 33 filings, for trades running from 5 October 2020 to 2 October 2024.
No open-market purchase appears, only 16 sales worth €1.8M. Besides market trades, the filings include 4 share grants and 12 option exercises. In 2024 alone, the filings show no purchases and 16 sales.
On 4 October 2024 came the latest disclosure, a transaction for €16k in Augmedix, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations